E Van Caenegem1, K Wierckx2, Y Taes3, T Schreiner2, S Vandewalle3, K Toye3, B Lapauw3, J-M Kaufman3, G T'Sjoen4. 1. Department of EndocrinologyGhent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumEuropean Network for the Investigation of Gender Incongruence (ENIGI)Ghent, BelgiumDepartment of EndocrinologyRikshospitalet, Oslo University Hospital, Sognsvannvn 20, Oslo, NorwayCenter for Sexology and Gender ProblemsGhent University Hospital, De Pintelaan 185, Ghent, Belgium Department of EndocrinologyGhent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumEuropean Network for the Investigation of Gender Incongruence (ENIGI)Ghent, BelgiumDepartment of EndocrinologyRikshospitalet, Oslo University Hospital, Sognsvannvn 20, Oslo, NorwayCenter for Sexology and Gender ProblemsGhent University Hospital, De Pintelaan 185, Ghent, Belgium eva.vancaenegem@ugent.be. 2. Department of EndocrinologyGhent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumEuropean Network for the Investigation of Gender Incongruence (ENIGI)Ghent, BelgiumDepartment of EndocrinologyRikshospitalet, Oslo University Hospital, Sognsvannvn 20, Oslo, NorwayCenter for Sexology and Gender ProblemsGhent University Hospital, De Pintelaan 185, Ghent, Belgium Department of EndocrinologyGhent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumEuropean Network for the Investigation of Gender Incongruence (ENIGI)Ghent, BelgiumDepartment of EndocrinologyRikshospitalet, Oslo University Hospital, Sognsvannvn 20, Oslo, NorwayCenter for Sexology and Gender ProblemsGhent University Hospital, De Pintelaan 185, Ghent, Belgium. 3. Department of EndocrinologyGhent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumEuropean Network for the Investigation of Gender Incongruence (ENIGI)Ghent, BelgiumDepartment of EndocrinologyRikshospitalet, Oslo University Hospital, Sognsvannvn 20, Oslo, NorwayCenter for Sexology and Gender ProblemsGhent University Hospital, De Pintelaan 185, Ghent, Belgium. 4. Department of EndocrinologyGhent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumEuropean Network for the Investigation of Gender Incongruence (ENIGI)Ghent, BelgiumDepartment of EndocrinologyRikshospitalet, Oslo University Hospital, Sognsvannvn 20, Oslo, NorwayCenter for Sexology and Gender ProblemsGhent University Hospital, De Pintelaan 185, Ghent, Belgium Department of EndocrinologyGhent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumEuropean Network for the Investigation of Gender Incongruence (ENIGI)Ghent, BelgiumDepartment of EndocrinologyRikshospitalet, Oslo University Hospital, Sognsvannvn 20, Oslo, NorwayCenter for Sexology and Gender ProblemsGhent University Hospital, De Pintelaan 185, Ghent, Belgium Department of EndocrinologyGhent University Hospital, De Pintelaan 185, 9000 Ghent, BelgiumEuropean Network for the Investigation of Gender Incongruence (ENIGI)Ghent, BelgiumDepartment of EndocrinologyRikshospitalet, Oslo University Hospital, Sognsvannvn 20, Oslo, NorwayCenter for Sexology and Gender ProblemsGhent University Hospital, De Pintelaan 185, Ghent, Belgium.
Abstract
PURPOSE: To assess the evolution of body composition and bone metabolism in trans men during the first year of cross-sex hormonal therapy. METHODS: In a prospective controlled study, we included 23 trans men (female-to-male trans persons) and 23 age-matched control women. In both groups, we examined grip strength (hand dynamometer), biochemical markers of bone turnover (C-terminal telopeptides of type 1 collagen (CTX) and procollagen 1 aminoterminal propeptide (P1NP)), total body fat and lean mass, and areal bone mineral density (aBMD) by dual-X-ray absorptiometry (DXA) and fat and muscle area at the forearm and calf, bone geometry, and volumetric bone mineral density (vBMD) by peripheral quantitative computed tomography (pQCT), before treatment and after 1 year of treatment with undecanoate (1000 mg i.m./12 weeks). RESULTS: Before hormonal treatment, trans men had similar bone and body composition compared with control women. Testosterone treatment induced in trans men a gain in muscle mass (+10.4%) and strength and loss of fat mass (-9.7%) (all P<0.001) and increased the levels of P1NP and CTX (both P<0.01). Areal and volumetric bone parameters remained largely unchanged apart from a small increase in trabecular vBMD at the distal radius and in BMD at the total hip in trans men (P=0.036 and P=0.001 respectively). None of these changes were observed in the control group. CONCLUSIONS: Short-term testosterone treatment in trans men increased muscle mass and bone turnover. The latter may rather reflect an anabolic effect of testosterone treatment rather than bone loss.
PURPOSE: To assess the evolution of body composition and bone metabolism in trans men during the first year of cross-sex hormonal therapy. METHODS: In a prospective controlled study, we included 23 trans men (female-to-male trans persons) and 23 age-matched control women. In both groups, we examined grip strength (hand dynamometer), biochemical markers of bone turnover (C-terminal telopeptides of type 1 collagen (CTX) and procollagen 1 aminoterminal propeptide (P1NP)), total body fat and lean mass, and areal bone mineral density (aBMD) by dual-X-ray absorptiometry (DXA) and fat and muscle area at the forearm and calf, bone geometry, and volumetric bone mineral density (vBMD) by peripheral quantitative computed tomography (pQCT), before treatment and after 1 year of treatment with undecanoate (1000 mg i.m./12 weeks). RESULTS: Before hormonal treatment, trans men had similar bone and body composition compared with control women. Testosterone treatment induced in trans men a gain in muscle mass (+10.4%) and strength and loss of fat mass (-9.7%) (all P<0.001) and increased the levels of P1NP and CTX (both P<0.01). Areal and volumetric bone parameters remained largely unchanged apart from a small increase in trabecular vBMD at the distal radius and in BMD at the total hip in trans men (P=0.036 and P=0.001 respectively). None of these changes were observed in the control group. CONCLUSIONS: Short-term testosterone treatment in trans men increased muscle mass and bone turnover. The latter may rather reflect an anabolic effect of testosterone treatment rather than bone loss.
Authors: E Castellano; C Crespi; C Dell'Aquila; R Rosato; C Catalano; V Mineccia; G Motta; E Botto; C Manieri Journal: J Endocrinol Invest Date: 2015-12 Impact factor: 4.256
Authors: John David Fernandez; Katherine Kendjorsky; Ana Narla; Alejandro G Villasante-Tezanos; Lisa R Tannock Journal: LGBT Health Date: 2019-02-27 Impact factor: 4.151
Authors: Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas Journal: Physiol Rev Date: 2017-01 Impact factor: 37.312
Authors: A D Fisher; G Senofonte; C Cocchetti; G Guercio; V Lingiardi; M C Meriggiola; M Mosconi; G Motta; J Ristori; A M Speranza; M Pierdominici; M Maggi; G Corona; F Lombardo Journal: J Endocrinol Invest Date: 2021-10-22 Impact factor: 4.256
Authors: E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus Journal: Int J Transgend Health Date: 2022-09-06
Authors: Sari L Reisner; Madeline B Deutsch; Shalender Bhasin; Walter Bockting; George R Brown; Jamie Feldman; Rob Garofalo; Baudewijntje Kreukels; Asa Radix; Joshua D Safer; Vin Tangpricha; Guy TʼSjoen; Michael Goodman Journal: Curr Opin Endocrinol Diabetes Obes Date: 2016-04 Impact factor: 3.243
Authors: Jamie Feldman; George R Brown; Madeline B Deutsch; Wylie Hembree; Walter Meyer; Heino F L Meyer-Bahlburg; Vin Tangpricha; Guy TʼSjoen; Joshua D Safer Journal: Curr Opin Endocrinol Diabetes Obes Date: 2016-04 Impact factor: 3.243
Authors: Maria Atc van der Loos; Ilse Hellinga; Mariska C Vlot; Daniel T Klink; Martin den Heijer; Chantal M Wiepjes Journal: J Bone Miner Res Date: 2021-02-17 Impact factor: 6.741